Catheter ablation treatment for people with atrial fibrillation
A Prospective Cohort Study of Atrial Fibrillation Patients Treated With Catheter Ablation
This project will try radiofrequency catheter ablation in adults with non-valvular atrial fibrillation to see if it improves atrial function and quality of life and to identify who is likely to have recurrence.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 300 (estimated) |
| Ages | 18 Years to 80 Years |
| Sex | All |
| Sponsor | Peking Union Medical College Hospital Academic / other |
| Locations | 1 site (Beijing, Beijing Municipality) |
| Trial ID | NCT05266144 on ClinicalTrials.gov |
What this trial studies
This single-center prospective observational cohort will follow adults with non-valvular atrial fibrillation who undergo radiofrequency catheter ablation at Peking Union Medical College Hospital. Researchers will collect baseline clinical data and measure serologic markers of atrial fibrosis, transthoracic echocardiography, cardiac MRI, atrial potential mapping, quality-of-life questionnaires, and long-term ECG monitoring within one week after ablation. They will use these multidimensional data to build a predictive model for atrial fibrillation recurrence after ablation and analyze relationships between noninvasive measures of fibrosis, atrial electrical activity, and atrial function. Patients with evidence of ventricular fibrosis will be selected for gene sequencing to search for underlying cardiomyopathy and to provide data for further research.
Who should consider this trial
Good fit: Adults aged 18–80 with non-valvular paroxysmal or persistent atrial fibrillation, a left atrial anteroposterior diameter <50 mm, and who are eligible and consenting for bilateral pulmonary vein isolation are ideal candidates.
Not a fit: People with valvular atrial disease, prior AF ablation, active hyperthyroidism, intra-atrial thrombus, or those outside the specified age or left atrial size limits are unlikely to benefit from this protocol.
Why it matters
Potential benefit: If successful, the work could help predict which patients are most likely to have AF recurrence after ablation and guide more personalized follow-up and treatment.
How similar studies have performed: Radiofrequency ablation is an established treatment with many studies showing clinical benefit, but combining imaging, serologic fibrosis markers, electrical mapping, and genomics to predict recurrence is a relatively novel, emerging approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Non-valvular atrial fibrillation, including paroxysmal atrial fibrillation and persistent atrial fibrillation * 18-80 years old * The anteroposterior diameter of the left atrium is less than 50mm via TTE * Patient meets the intervention criteria for bilateral pulmonary vein isolation after evaluation by electrophysiological specialists * Patient consents to ablation treatment Exclusion Criteria: * Intra-atrial thrombus detected by TEE * Hyperthyroidism * Previous radiofrequency ablation for atrial fibrillation
Where this trial is running
Beijing, Beijing Municipality
- Peking Union Medical College Hospital — Beijing, Beijing Municipality, China (Recruiting)
Study contacts
- Principal investigator: Yongtai Liu, M.D. — Peking Union Medical College Hospital
- Study coordinator: Yongtai Liu, M.D.
- Email: ataiever@163.com
- Phone: +86-1069155068
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.